We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Cell-Based Assays Recommended for Autoantibody Detection in Demyelinating Diseases

By LabMedica International staff writers
Posted on 05 Dec 2023
Print article
Image: NMOSD is associated with pathogenic antibodies against the CNS water-channel protein aquaporin-4 (AQP-4) (Photo courtesy of EUROIMMUN)
Image: NMOSD is associated with pathogenic antibodies against the CNS water-channel protein aquaporin-4 (AQP-4) (Photo courtesy of EUROIMMUN)

Neuromyelitis optica spectrum disorders (NMOSD) are acquired demyelinating disorders of the central nervous system (CNS) that affect the optic nerves, spinal cord and brainstem. NMOSD must be diagnostically distinguished from the more common demyelinating disease multiple sclerosis (MS), which can resemble NMOSD in the initial stages but has different therapy requirements. Autoantibodies against the CNS water-channel protein aquaporin-4 (AQP4) are pathogenic for NMOSD and represent a highly specific diagnostic biomarker. Autoantibodies against myelin oligodendrocyte glycoprotein (MOG) are a marker for MOG antibody-associated diseases (MOGAD), which have clinical and radiological overlap with NMOSD. Now, the 2023 recommendations for the diagnosis of NMOSD stipulate that cell-based assays (CBA) are the gold standard for the detection of autoantibodies against AQP4 and MOG.

AQP4-IgG is a mandatory diagnostic test for NMOSD, while MOG-IgG testing is recommended in AQP4 antibody-negative cases and for differential diagnostics. Determination of both AQP4-IgG and MOG-IgG antibodies helps to delimit the diseases from each other and from classic MS. The new recommendations from the Neuromyelitis Optica Study Group (NEMOS) stipulate that both AQP4-IgG and MOG-IgG antibodies must be tested by CBA. The assays must employ cells expressing conformationally intact, full-length recombinant human AQP4 or MOG protein, respectively, as the antigenic substrate and include a control substrate, preferably mock-transfected cells. Other methods such as immunohistochemistry, ELISA, fluorescence-based immunoprecipitation, western blot, and RIA are less sensitive and specific and should no longer be employed for routine clinical testing.

CBAs for AQP4 and MOG antibodies from EUROIMMUN (Lübeck, Germany) meet the recommended requirements. The assays are based on transfected human cell lines expressing the corresponding full-length target antigen and include a control-transfected substrate which is incubated in parallel. EUROIMMUN’s CBA technology enables intact presentation of the fragile conformation-dependent antigens, allowing highly sensitive antibody detection. Moreover, the company’s BIOCHIP Mosaic technology enables easy parallel incubation of different substrates. Miniature sections of the antigen-expressing cells and control-transfected cells are positioned side by side in the fields of a microscope slide and incubated with one patient sample.

Further, AQP4 and MOG antibodies can be analyzed simultaneously using a mosaic containing both AQP4- and MOG-transfected cell substrates together with a control. The EUROIMMUN NMOSD Screen 1 is currently the only commercially available multiparameter CBA for AQP4-IgG and MOG-IgG. All EUROIMMUN assays for anti-AQP4 and anti-MOG antibodies are CE-marked. The analysis procedure is simple and can be performed in any laboratory familiar with indirect immunofluorescence. Automation options are available to facilitate the processing and evaluation. The tests are validated for automated microscopy using the EUROPattern Microscope and the EUROPattern Microscope Live.

Related Links:
EUROIMMUN

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.